Do analysts recommend MENS or IXHL?

Incannex Healthcare has a consensus target price of $18.00, indicating a potential upside of 404.20%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, analysts plainly believe Incannex Healthcare is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, MENS or IXHL?

Jyong Biotech has higher earnings, but lower revenue than Incannex Healthcare. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Incannex Healthcare $90K 474.81 -$46.88M -$1.55 N/A

Is MENS or IXHL more profitable?

Jyong Biotech's return on equity of 0.00% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Incannex Healthcare N/A -81.01% -76.11%

Is IXHL or UNCY more profitable?

Incannex Healthcare's return on equity of -81.01% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% Unicycive Therapeutics N/A -91.50% -61.47%

Is IXHL or AARD more profitable?

Aardvark Therapeutics' return on equity of -71.54% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% Aardvark Therapeutics N/A -71.54% -64.94%

Is IXHL or MIST more profitable?

Incannex Healthcare's return on equity of -81.01% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% Milestone Pharmaceuticals N/A -288.33% -58.27%

Incannex Healthcare (IXHL) Competitors

$3.57 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

IXHL vs. MENS, UNCY, LENZ, AARD, and MIST

Should you buy Incannex Healthcare stock or one of its competitors? Incannex Healthcare's main competitors and comparable companies include Jyong Biotech (MENS), Unicycive Therapeutics (UNCY), LENZ Therapeutics (LENZ), Aardvark Therapeutics (AARD), and Milestone Pharmaceuticals (MIST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Incannex Healthcare compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

0.4% of Incannex Healthcare shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Jyong Biotech's average media sentiment score of 0.00 equaled Incannex Healthcare'saverage media sentiment score.

Company	Overall Sentiment
Jyong Biotech	Neutral
Incannex Healthcare	Neutral

Jyong Biotech has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.98, meaning that its stock price is 598% more volatile than the broader market.

Jyong Biotech has higher earnings, but lower revenue than Incannex Healthcare.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Incannex Healthcare	$90K	474.81	-$46.88M	-$1.55	N/A

Jyong Biotech's return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Incannex Healthcare	N/A	-81.01%	-76.11%

Incannex Healthcare has a consensus target price of $18.00, indicating a potential upside of 404.20%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, analysts plainly believe Incannex Healthcare is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Incannex Healthcare beats Jyong Biotech on 7 of the 10 factors compared between the two stocks.

How does Incannex Healthcare compare to Unicycive Therapeutics?

Incannex Healthcare (NASDAQ:IXHL) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Unicycive Therapeutics has higher revenue and earnings than Incannex Healthcare. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	474.81	-$46.88M	-$1.55	N/A
Unicycive Therapeutics	$680K	230.58	-$26.56M	-$1.75	N/A

In the previous week, Unicycive Therapeutics had 3 more articles in the media than Incannex Healthcare. MarketBeat recorded 3 mentions for Unicycive Therapeutics and 0 mentions for Incannex Healthcare. Unicycive Therapeutics' average media sentiment score of 0.76 beat Incannex Healthcare's score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Incannex Healthcare	Neutral
Unicycive Therapeutics	Positive

Incannex Healthcare has a beta of 6.98, indicating that its stock price is 598% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Incannex Healthcare currently has a consensus target price of $18.00, indicating a potential upside of 404.20%. Unicycive Therapeutics has a consensus target price of $18.75, indicating a potential upside of 233.04%. Given Incannex Healthcare's higher possible upside, analysts plainly believe Incannex Healthcare is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Incannex Healthcare's return on equity of -81.01% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Summary

Unicycive Therapeutics beats Incannex Healthcare on 9 of the 15 factors compared between the two stocks.

How does Incannex Healthcare compare to LENZ Therapeutics?

Incannex Healthcare (NASDAQ:IXHL) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Incannex Healthcare currently has a consensus price target of $18.00, suggesting a potential upside of 404.20%. LENZ Therapeutics has a consensus price target of $28.80, suggesting a potential upside of 515.38%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Incannex Healthcare has higher earnings, but lower revenue than LENZ Therapeutics. Incannex Healthcare is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	474.81	-$46.88M	-$1.55	N/A
LENZ Therapeutics	$19.09M	7.70	-$82.13M	-$4.09	N/A

In the previous week, LENZ Therapeutics had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 2 mentions for LENZ Therapeutics and 0 mentions for Incannex Healthcare. LENZ Therapeutics' average media sentiment score of 0.51 beat Incannex Healthcare's score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Incannex Healthcare	Neutral
LENZ Therapeutics	Positive

Incannex Healthcare has a beta of 6.98, meaning that its share price is 598% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

Incannex Healthcare has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. LENZ Therapeutics' return on equity of -53.39% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

Summary

LENZ Therapeutics beats Incannex Healthcare on 11 of the 16 factors compared between the two stocks.

How does Incannex Healthcare compare to Aardvark Therapeutics?

Incannex Healthcare (NASDAQ:IXHL) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

In the previous week, Aardvark Therapeutics had 26 more articles in the media than Incannex Healthcare. MarketBeat recorded 26 mentions for Aardvark Therapeutics and 0 mentions for Incannex Healthcare. Aardvark Therapeutics' average media sentiment score of 0.05 beat Incannex Healthcare's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Incannex Healthcare	Neutral
Aardvark Therapeutics	Neutral

Incannex Healthcare presently has a consensus target price of $18.00, suggesting a potential upside of 404.20%. Aardvark Therapeutics has a consensus target price of $16.30, suggesting a potential upside of 139.00%. Given Incannex Healthcare's higher possible upside, research analysts clearly believe Incannex Healthcare is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Incannex Healthcare has a beta of 6.98, meaning that its stock price is 598% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.8, meaning that its stock price is 280% more volatile than the broader market.

Aardvark Therapeutics' return on equity of -71.54% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Aardvark Therapeutics	N/A	-71.54%	-64.94%

Incannex Healthcare has higher revenue and earnings than Aardvark Therapeutics. Incannex Healthcare is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	474.81	-$46.88M	-$1.55	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

0.4% of Incannex Healthcare shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by company insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Aardvark Therapeutics beats Incannex Healthcare on 9 of the 15 factors compared between the two stocks.

How does Incannex Healthcare compare to Milestone Pharmaceuticals?

Incannex Healthcare (NASDAQ:IXHL) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Incannex Healthcare's return on equity of -81.01% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

Incannex Healthcare has higher earnings, but lower revenue than Milestone Pharmaceuticals. Incannex Healthcare is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	474.81	-$46.88M	-$1.55	N/A
Milestone Pharmaceuticals	$1.55M	84.74	-$63.06M	-$0.69	N/A

Incannex Healthcare has a beta of 6.98, meaning that its stock price is 598% more volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

Incannex Healthcare presently has a consensus price target of $18.00, suggesting a potential upside of 404.20%. Milestone Pharmaceuticals has a consensus price target of $6.40, suggesting a potential upside of 506.64%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Milestone Pharmaceuticals had 8 more articles in the media than Incannex Healthcare. MarketBeat recorded 8 mentions for Milestone Pharmaceuticals and 0 mentions for Incannex Healthcare. Milestone Pharmaceuticals' average media sentiment score of 0.18 beat Incannex Healthcare's score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Incannex Healthcare	Neutral
Milestone Pharmaceuticals	Neutral

Summary

Milestone Pharmaceuticals beats Incannex Healthcare on 12 of the 16 factors compared between the two stocks.

Get Incannex Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXHL vs. The Competition

Export

Metric	Incannex Healthcare	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$42.73M	$12.49B	$7.32B	$12.82B
Dividend Yield	N/A	2.62%	2.54%	10.78%
P/E Ratio	-2.30	789.79	272.91	24.33
Price / Sales	474.81	795.68	639.67	97.25
Price / Cash	N/A	15.47	29.03	36.90
Price / Book	1.72	10.52	11.33	6.42
Net Income	-$46.88M	$2.81B	$3.47B	$348.89M
7 Day Performance	7.53%	2.51%	2.18%	0.51%
1 Month Performance	21.02%	5.08%	7.61%	4.84%
1 Year Performance	-79.76%	7.28%	25.16%	17.04%

Incannex Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXHL Incannex Healthcare	1.7947 of 5 stars	$3.57 flat	$18.00 +404.2%	-79.8%	$42.73M	$90K	N/A	3
MENS Jyong Biotech	N/A	$2.01 -0.5%	N/A	-95.3%	$153.58M	N/A	N/A	31
UNCY Unicycive Therapeutics	3.234 of 5 stars	$5.57 +1.1%	$18.25 +227.6%	+34.0%	$153.48M	$680K	N/A	9
LENZ LENZ Therapeutics	3.1862 of 5 stars	$4.79 +1.3%	$28.80 +501.3%	-88.3%	$148.62M	$19.09M	N/A	110
AARD Aardvark Therapeutics	2.3573 of 5 stars	$6.74 +3.1%	$16.30 +141.8%	-30.2%	$143.12M	N/A	N/A	18	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IXHL) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incannex Healthcare (IXHL) Competitors

IXHL vs. MENS, UNCY, LENZ, AARD, and MIST

How does Incannex Healthcare compare to Jyong Biotech?

Summary

How does Incannex Healthcare compare to Unicycive Therapeutics?

Summary

How does Incannex Healthcare compare to LENZ Therapeutics?

Summary

How does Incannex Healthcare compare to Aardvark Therapeutics?

Summary

How does Incannex Healthcare compare to Milestone Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Incannex Healthcare (IXHL) Competitors

IXHL vs. MENS, UNCY, LENZ, AARD, and MIST

How does Incannex Healthcare compare to Jyong Biotech?

Do insiders & institutionals hold more shares of MENS or IXHL?

Does the media refer more to MENS or IXHL?

Which has more risk & volatility, MENS or IXHL?

Which has better valuation & earnings, MENS or IXHL?

Is MENS or IXHL more profitable?

Do analysts recommend MENS or IXHL?

Summary

How does Incannex Healthcare compare to Unicycive Therapeutics?

Which has higher earnings and valuation, IXHL or UNCY?

Does the media refer more to IXHL or UNCY?

Which has more risk & volatility, IXHL or UNCY?

Do analysts rate IXHL or UNCY?

Do institutionals & insiders believe in IXHL or UNCY?

Is IXHL or UNCY more profitable?

Summary

How does Incannex Healthcare compare to LENZ Therapeutics?

Do analysts rate IXHL or LENZ?

Do insiders & institutionals have more ownership in IXHL or LENZ?

Which has better earnings & valuation, IXHL or LENZ?

Does the media prefer IXHL or LENZ?

Which has more volatility & risk, IXHL or LENZ?

Is IXHL or LENZ more profitable?

Summary

How does Incannex Healthcare compare to Aardvark Therapeutics?

Does the media favor IXHL or AARD?

Do analysts recommend IXHL or AARD?

Which has more volatility and risk, IXHL or AARD?

Is IXHL or AARD more profitable?

Which has higher valuation & earnings, IXHL or AARD?

Do insiders and institutionals have more ownership in IXHL or AARD?

Summary

How does Incannex Healthcare compare to Milestone Pharmaceuticals?

Is IXHL or MIST more profitable?

Which has stronger valuation & earnings, IXHL or MIST?

Which has more risk and volatility, IXHL or MIST?

Do analysts prefer IXHL or MIST?

Do institutionals & insiders hold more shares of IXHL or MIST?

Does the media refer more to IXHL or MIST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools